TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35224215

Group type: EXPERIMENTAL
Intervention: Vaginal washing with 20 cc of normal saline 0.9% before Misoprostol insertion
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (without vaginal washing)
Number of subjects: 148
Study: 33176826

Group type: EXPERIMENTAL
Intervention: Encapsulated natural mushroom-derived vitamin D2 (25 μg or 1000 IU)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Matched-dose encapsulated vitamin D3 (25 μg or 1000 IU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28
Study: 35288397

Group type: EXPERIMENTAL
Intervention: 25 mg empagliflozin for 14 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Matching placebo for 14 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Empagliflozin and placebo
Number of subjects: 46
Study: 33547689

Group type: EXPERIMENTAL
Intervention: Spiral readouts with long waveform (45 ms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spiral readouts with short waveform (26 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: f0-map correction
Number of subjects: 0
Study: 32423126

Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined Power Training and Traditional Resistance Training (PTRT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study: 35597230

Group type: EXPERIMENTAL
Intervention: Higher anthocyanin intake (>10 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lower anthocyanin intake (<10 mg/d)
Number of subjects: 40
Study: 32895971

Group type: EXPERIMENTAL
Intervention: Enteral erythromycin estolate (250 mg) + Intravenous metoclopramide (10 mg every 6-8 hours)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intravenous metoclopramide (10 mg every 6-8 hours) + Placebo (every 6 hours for 7 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 34275664

Group type: EXPERIMENTAL
Intervention: FLACS-I
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: FLACS-II
Number of subjects: 167

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 167
Study: 32032916

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.2 mg.kg‐1
Number of subjects: 61

Group type: COMPARATOR
Intervention: Dexamethasone 0.1 mg.kg‐1
Number of subjects: 61
Study: 36241872

Group type: EXPERIMENTAL
Intervention: ivabradine (5-7.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34010787

Group type: EXPERIMENTAL
Intervention: ALLR3 trial
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Induction therapy with good MRD response
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Post-SCT for BCP-ALL
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Post-SCT for T-ALL
Number of subjects: 393
Study: 32808034

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 336997

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 336997

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 336997

Group type: EXPERIMENTAL
Intervention: BMI, Alcohol intake, Smoking
Number of subjects: 336997

Group type: EXPERIMENTAL
Intervention: Depression, Asthma, Migraines
Number of subjects: 336997
Study: 36328383

Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case (BC/WC) communication tool training for nephrologists
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study: 35952316

Group type: EXPERIMENTAL
Intervention: Immunoscore-High tumors in low-risk group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Immunoscore-Low tumors in low-risk group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Immunoscore-High tumors in high-risk group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Immunoscore-Low tumors in high-risk group
Number of subjects: 600

Group type: COMPARATOR
Intervention: Low-risk/Immunoscore-Low tumors
Number of subjects: 600
Study: 33030349

Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (Routine breast care)
Number of subjects: 67
Study: 32658890

Group type: EXPERIMENTAL
Intervention: Higher baseline skin autofluorescence (SAF)
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Increase in SAF over 1 year
Number of subjects: 1707
Study: 36055959

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 260
Study: 36299233

Group type: EXPERIMENTAL
Intervention: Fungitell® beta-D-glucan (BDG) assay
Number of subjects: 51
Study: 34625409

Group type: EXPERIMENTAL
Intervention: Remote methods of genetic education about the risks of inherited PDAC and strategies for surveillance.
Number of subjects: 98
Study: 32044712

Group type: EXPERIMENTAL
Intervention: veridical rt‐fMRI‐nf
Number of subjects: 32

Group type: COMPARATOR
Intervention: sham (yoked) feedback
Number of subjects: 32
Study: 35373583

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 229

Group type: COMPARATOR
Intervention: Dual Antiplatelet Therapy (aspirin plus clopidogrel)
Number of subjects: 229
Study: 34768338

Group type: EXPERIMENTAL
Intervention: Automated oxygen titration
Number of subjects: 33

Group type: COMPARATOR
Intervention: Fixed-dose oxygen treatment
Number of subjects: 33
Study: 32951712

Group type: EXPERIMENTAL
Intervention: Vacuum myofascial therapy device (VT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison physical therapy program (PTP)
Number of subjects: 38
Study: 33189285

Group type: EXPERIMENTAL
Intervention: Acetate (6 mM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapamycin (100 nM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eIF4E siRNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (0 mM acetate)
Number of subjects: 0
Study: 34872625

Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (CBT) for ED-PTSD
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard CBT for ED
Number of subjects: 42
Study: 36461632

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study: 34597010

Group type: EXPERIMENTAL
Intervention: Robotic mastectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 80
Study: 34140460

Group type: EXPERIMENTAL
Intervention: Internet CBT (Pancreatitis Pain Course)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 32769842

Group type: EXPERIMENTAL
Intervention: Lotrafilcon B lenses packaged in and cared for with EOBO-containing solutions (CLEAR CARE PLUS with HydraGlyde or OPTI-FREE PUREMOIST)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Senofilcon C lenses with non-EOBO MPS
Number of subjects: 143

Group type: COMPARATOR
Intervention: Senofilcon A lenses with non-EOBO MPS
Number of subjects: 143

Group type: COMPARATOR
Intervention: Comfilcon A lenses with non-EOBO MPS
Number of subjects: 143

Group type: COMPARATOR
Intervention: Samfilcon A lenses with non-EOBO MPS
Number of subjects: 143
Study: 36397223

Group type: EXPERIMENTAL
Intervention: Five-element music therapy, 30 min each session, once every two days, 3 treatments a week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional health education (control group).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Five-element music therapy.
Number of subjects: 60
Study: 33857180

Group type: EXPERIMENTAL
Intervention: Schroth exercises
Number of subjects: 28

Group type: COMPARATOR
Intervention: Core stabilization exercises
Number of subjects: 28
Study: 36129521

Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 13, standard dose every 10 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: NB‐UVB (n = 11, thrice weekly)
Number of subjects: 24
Study: 33423540

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Warfarin plus aspirin
Number of subjects: 94
Study: 32383615

Group type: EXPERIMENTAL
Intervention: Aminophylline (5mg/kg slow intravenous injection)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (2 mL/kg of intravenous 10% solution of dextrose saline)
Number of subjects: 56
Study: 32298600

Group type: EXPERIMENTAL
Intervention: Hala system
Number of subjects: 160

Group type: COMPARATOR
Intervention: Research survey system
Number of subjects: 160
Study: 34534071

Group type: EXPERIMENTAL
Intervention: 5-week adjunctive bright light therapy with a gradual advance protocol
Number of subjects: 91
Study: 32001805

Group type: EXPERIMENTAL
Intervention: Genetic ancestry analysis using a panel of 192 polymorphic markers
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Increased African genetic ancestry
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 1358
Study: 35726738

Group type: EXPERIMENTAL
Intervention: Colorado Protocol (aspirin, steroid, and antibiotic)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo arm of a trial
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Colorado Protocol
Number of subjects: 289
Study: 33436380

Group type: EXPERIMENTAL
Intervention: Educational intervention targeting managers with a 3-hour seminar addressing needs and options for adjustment of work in pregnancy.
Number of subjects: 915

Group type: COMPARATOR
Intervention: Control group with practice as usual.
Number of subjects: 915
Study: 32977216

Group type: EXPERIMENTAL
Intervention: Massage (10-20 minutes per session)
Number of subjects: 2494

Group type: EXPERIMENTAL
Intervention: Acupoint or specific body reflex area massage
Number of subjects: 2494

Group type: EXPERIMENTAL
Intervention: Massage delivered by professionals and non-professionals
Number of subjects: 2494

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 2494
Study: 35791755

Group type: EXPERIMENTAL
Intervention: Mirikizumab 250 mg Q4W
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Mirikizumab 250 mg Q4W/125 mg Q8W
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Mirikizumab 250 mg Q4W/250 mg Q8W
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 33080034

Group type: EXPERIMENTAL
Intervention: Bright light treatment (10,000 lux)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Red dim light (100 lux)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bright light treatment
Number of subjects: 35
Study: 35063011

Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization (DNS) exercise
Number of subjects: 64

Group type: COMPARATOR
Intervention: Core stability (CS) exercises
Number of subjects: 64
Study: 34798030

Group type: COMPARATOR
Intervention: Handwashing stations only
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Theory of normative social behaviour (TNSB) intervention including provision of handwashing stations
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study: 32585673

Group type: EXPERIMENTAL
Intervention: Robotic surgery (ROB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Open surgery (OPEN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (motor training without surgical instruments)
Number of subjects: 40
Study: 34932153

Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 50
Study: 32273219

Group type: EXPERIMENTAL
Intervention: Mouth Care Without a Battle (MCWB) intervention
Number of subjects: 434

Group type: COMPARATOR
Intervention: Control group (non-MCWB homes)
Number of subjects: 434
Study: 35737952

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Swaddling
Number of subjects: 100
Study: 34088821

Group type: EXPERIMENTAL
Intervention: Connection to Health (CTH) - 6 practices, consisting of a health survey followed by collaborative action planning
Number of subjects: 725

Group type: COMPARATOR
Intervention: Enhanced Engagement CTH (EE-CTH) - 6 practices, including additional training in relationship building promoting patient engagement
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Higher health literacy
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: No social risks
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Higher quality action plans
Number of subjects: 725
Study: 35144067

Group type: EXPERIMENTAL
Intervention: Labour roadmap with birth balls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 35534825

Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 35080187

Group type: EXPERIMENTAL
Intervention: Bevacizumab 2.5 mg/kg d1, d8 (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg d1, d8 (group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg d1, d8 (group C)
Number of subjects: 20
Study: 34530885

Group type: EXPERIMENTAL
Intervention: Isolation procedure (arm B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional procedure (arm A)
Number of subjects: 100
Study: 35701011

Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 33255704

Group type: EXPERIMENTAL
Intervention: Psychological Capital Intervention (PCI) using a daily online self-learning approach
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study: 616886769

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine-based nursing care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 60
Study: 35801287

Group type: EXPERIMENTAL
Intervention: Biodex training
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Classical balance training
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 32901526

Group type: EXPERIMENTAL
Intervention: Liposomal vitamin C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-liposomal vitamin C
Number of subjects: 0
Study: 32056053

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 1193
Study: 33040208

Group type: EXPERIMENTAL
Intervention: Kinematically aligned total knee arthroplasty (KA TKA) with a posterior-stabilizing (PS) prosthesis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) total knee arthroplasty (TKA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Posterior-stabilizing (PS) total knee arthroplasty (TKA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mechanically aligned total knee arthroplasty (MA TKA) with a PS prosthesis
Number of subjects: 14
Study: 32329033

Group type: EXPERIMENTAL
Intervention: FIT intervention
Number of subjects: 352
Study: 35433385

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 80
Study: 32410636

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) technique
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard Free-Hand (FH) technique
Number of subjects: 160
Study: 35613184

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 4274

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4274
Study: 32706502

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 35759004

Group type: EXPERIMENTAL
Intervention: State-funded pre-kindergarten (pre-K) program
Number of subjects: 2990
Study: 32696031

Group type: EXPERIMENTAL
Intervention: Systemic moxifloxacin (MXF) with subgingival debridement (SD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus metronidazole (AM+MT) combined with SD
Number of subjects: 36

Group type: COMPARATOR
Intervention: Subgingival debridement (SD) alone
Number of subjects: 36
Study: 32581088

Group type: EXPERIMENTAL
Intervention: Rituximab (4×375 mg/m2) and glucocorticoids (higher or lower dose regimen)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Rituximab and glucocorticoids
Number of subjects: 188
Study: 36328390

Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treadmill gait training alone
Number of subjects: 0
Study: 32686996

Group type: EXPERIMENTAL
Intervention: IAI-Programme
Number of subjects: 36

Group type: COMPARATOR
Intervention: FIFA11+
Number of subjects: 36
Study: 34211330

Group type: EXPERIMENTAL
Intervention: early‐pubertal training
Number of subjects: 178

Group type: COMPARATOR
Intervention: early‐pubertal control
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: post‐pubertal training
Number of subjects: 178

Group type: COMPARATOR
Intervention: post‐pubertal control
Number of subjects: 178
Study: 35443845

Group type: EXPERIMENTAL
Intervention: Threat agency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human agency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threat agency for threats not ascribed to humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threat agency for threats ascribed to humans
Number of subjects: 0
Study: 33951241

Group type: EXPERIMENTAL
Intervention: Masked and very briefly presented food images
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clearly visible food images
Number of subjects: 60

Group type: COMPARATOR
Intervention: Masked non-food images (household items)
Number of subjects: 60
Study: 32422870

Group type: EXPERIMENTAL
Intervention: Seapolynol isolated from Ecklonia cava
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36183042

Group type: EXPERIMENTAL
Intervention: Subtenon 20-mg triamcinolone injection (TA group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: 0.1% dexamethasone eye drops (Dexa group)
Number of subjects: 140
Study: 32701208

Group type: EXPERIMENTAL
Intervention: Relative afferent pupillary defect (RAPD) assessment at diagnosis or one month
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Severe RAPD or visual acuity (VA) < 35 letters (ETDRS) at inclusion or at one month
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: RAPD assessment
Number of subjects: 101
Study: 32767988

Group type: EXPERIMENTAL
Intervention: Mastectomy combined with flap fixation and closed-suction drainage
Number of subjects: 250

Group type: COMPARATOR
Intervention: Mastectomy combined with flap fixation without drainage
Number of subjects: 250
Study: 34699409

Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg once daily for 28 days
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 34069892

Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 16
Study: 35372547

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver (ARM)
Number of subjects: 21

Group type: COMPARATOR
Intervention: PEEP (5 cmH2O)
Number of subjects: 21
Study: 32446842

Group type: EXPERIMENTAL
Intervention: Cooling anesthesia at -10° C
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard of care (SOC) lidocaine-based anesthesia
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cooling anesthesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 22
Study: 34756414

Group type: EXPERIMENTAL
Intervention: Vacuum sealing drainage (VSD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional drainage
Number of subjects: 120
Study: 32935921

Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring (FGM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Self-Monitored Blood Glucose (SMBG)
Number of subjects: 64
Study: 35842121

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 77
Study: 33278504

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (n = 11)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham tDCS (n = 10)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy volunteers (n = 10)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Migraineurs (n = 25)
Number of subjects: 25
Study: 32988518

Group type: EXPERIMENTAL
Intervention: Feeding frequency 3 times daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Feeding frequency 4 times daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ad libitum feeding
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Different feeding frequencies (3 to 5 times daily)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Different feeding frequencies
Number of subjects: 240
Study: 33211292

Group type: EXPERIMENTAL
Intervention: Farmed fish (Oreochromis niloticus)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Natural source fish (Prochilodus magdalenae and Pimelodus grosskopfii)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Tissue types (stomach, gill, flesh)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Identified microplastics
Number of subjects: 208
Study: 36336624

Group type: EXPERIMENTAL
Intervention: Biophilic virtual reality (BVR)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Indoor virtual reality (IVR)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 106
Study: 33449304

Group type: EXPERIMENTAL
Intervention: Capsaicinoids at 10 μmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicinoids preconditioning at 10 μmol/L over 5 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicinoids at 50 μmol/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-carbonated water (control)
Number of subjects: 0
Study: 32573158

Group type: EXPERIMENTAL
Intervention: Lumbosacral approach group
Number of subjects: 87

Group type: COMPARATOR
Intervention: Buttock approach group
Number of subjects: 87
Study: 34542698

Group type: EXPERIMENTAL
Intervention: Computed tomography (Pöschl projection) and subsequent dissection by milling
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Arcuate eminence classified as flat (1 mm)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Arcuate eminence classified as prominent (1-2 mm)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Arcuate eminence classified as very prominent (above 2 mm)
Number of subjects: 295